Filter by year
-
march272018
Shareholders accepted all motions at the AGM 2018
-
march12018
Newron announces 2017 financial results and provides outlook for 2018
-
february132018
Newron Supports Global Rare Disease Day® 2018 and Rett Syndrome Studies
-
february82018
Change in the Board of Directors
-
february12018
Primary endpoint met in phase II/III clinical study of investigational Parkinson’s disease treatment safinamide in Japan